准确的分期和反应评估对淋巴瘤患者的预后和治疗至关重要。本研究旨在比较FDG PET/MRI与FDG PET/CT在初诊何奇金和非何奇金淋巴瘤成人患者中的诊断表现。在这个单一中心的研究中，招募了50名患者。使用一次18F-FDG的注射后进行了分期FDG PET/CT，然后进行FDG PET/MRI。在治疗反应评估期间，邀请患者同日完成FDG PET/MRI和FDG PET/CT。使用PET/CT作为疾病位置确认、分期、Deauville评分反应评估和代谢活性一致性的参考标准进行评估。分期评估显示，使用Ann Arbor分期PET/MRI和PET/CT完全一致（κ = 1.0，P = 0）。在分期中，FDG PET/MRI的灵敏度为96%（95％CI，94-98％），特异度为100%（95％CI，99-100％），疾病位置确认的模态间一致性非常好（κ = 0.976，P <0.001）。在治疗反应评估期间的疾病位置确认表现良好（κ = 0.819，P <0.001），而在治疗期末评估期间表现非常好（κ = 1.0，P <0.001）。模态间Deauville评分的一致性良好（治疗反应评估期间κ = 0.808，P <0.001；治疗结束评估期间κ = 1.0，P = 0）。在各个时间点，两种模态间SUV max和mean的一致性良好-非常好。每次扫描的最小计算辐射患者有效剂量节约达54％。由于疾病位置确认、分期和反应评估的高一致性，PET/MR是在淋巴瘤中可能是PET/CT的替代方案，同时可尽量减少辐射暴露。 ©2023作者。

Accurate staging and response assessment are essential for prognosis and to guide treatment in patients with lymphoma. The aim of this study was to compare the diagnostic performance of FDG PET/MRI versus FDG PET/CT in adult patients with newly diagnosed Hodgkin and Non- Hodgkin lymphoma.In this single centre study, 50 patients were prospectively recruited. FDG PET/MRI was performed after staging FDG PET/CT using a single injection of 18F-FDG. Patients were invited to complete same-day FDG PET/MRI with FDG PET/CT at interim and end of treatment response assessments. Performance was assessed using PET/CT as the reference standard for disease site identification, staging, response assessment with Deauville score and concordance in metabolic activity.Staging assessment showed perfect agreement (κ = 1.0, P = 0) between PET/MRI and PET/CT using Ann Arbor staging. There was excellent intermodality correlation with disease site identification at staging (κ = 0.976, P < 0.001) with FDG PET/MRI sensitivity of 96% (95% CI, 94-98%) and specificity of 100% (95% CI, 99-100%). There was good correlation of disease site identification at interim assessment (κ = 0.819, P < 0.001) and excellent correlation at end-of-treatment assessment (κ = 1.0, P < 0.001). Intermodality agreement for Deauville scores was good at interim assessment (κ = 0.808, P < 0.001) and excellent at end-of-treatment assessment (κ = 1.0, P = 0). There was good-excellent concordance in SUV max and mean between modalities across timepoints. Minimum calculated radiation patient effective dose saving was 54% between the two modalities per scan.With high concordance in disease site identification, staging and response assessment, PET/MR is a potentially viable alternative to PET/CT in lymphoma that minimises radiation exposure.© 2023. The Author(s).